Aptamer Therapy for Heart Failure?
Key result
Beta-1-adrenergic receptor autoantibodies are relatively prevalent (25%) in dilated cardiomyopathies and are being prospectively investigated in the ongoing ETiCS study.
Population
Heart failure patients, specifically subsets with peripartum, Chagas, and dilated cardiomyopathies of…
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
Discusses the potential pathophysiologic role of beta-1-adrenergic receptor autoantibodies in heart failure and the prospect of aptamer therapy.
Structured PICO
P
Population
Heart failure patients, specifically subsets with peripartum, Chagas, and dilated cardiomyopathies of idiopathic and ischemic origins
E
Exposure
Aptamer therapy
Discusses the potential pathophysiologic role of beta-1-adrenergic receptor autoantibodies in heart failure and the prospect of aptamer therapy.
Cite This Study
Port et al. (2011) conducted an editorial in Heart failure. Beta-1-adrenergic receptor autoantibodies was evaluated. Beta-1-adrenergic receptor autoantibodies are relatively prevalent (25%) in dilated cardiomyopathies and are being prospectively investigated in the ongoing ETiCS study.